Evaluation of Soluble Fiber as a Strategy to Decrease Asthma Morbidity in Underserved Populations

可溶性纤维作为降低服务不足人群哮喘发病率策略的评估

基本信息

  • 批准号:
    10707490
  • 负责人:
  • 金额:
    $ 33.53万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-09-20 至 2027-05-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Approximately 7.7% of the US population have asthma, and incidence has been increasing since the 1980s. In Arizona, asthma prevalence exceeds the national average, with the majority of asthma diagnoses made in the Phoenix Metropolitan Area. Genetic risk factors have been identified in asthmatics. However, the steady increase in the prevalence of asthma in the US population suggests that environmental exposures or other extrapulmonary factors, such as diet and the gut microbiota, may play a critical role in asthma development. Health disparities in asthma prevalence and morbidity are highlighted in individuals from low-income urban areas where nutritional health disparities are more likely to exist. For example, poor-urban residence is an individual risk factor for reporting an asthma attack and having higher odds for an asthma-related visit to the Emergency Department. Minority children are disproportionately affected by low socioeconomic status. A recent study demonstrated that 31.4% of non-Hispanic Black children, and 25.2% of Hispanic children lived under the poverty threshold compared to 9.4% non-Hispanic white children. Economically disadvantaged urban populations also experience a nutritional health disparity, including a low fiber diet that leads to shifts in the gut microbiome and may explain differences in asthma risk. Dietary fibers are complex carbohydrates that resist metabolism in the small intestine by host enzymes and are fermented in the colon by resident microbes. Gut microbial fermentation of soluble fibers results in production of metabolic by-products such as the short chain fatty acids (SCFAs) acetate, propionate, and butyrate, which are important molecules that act as a link between the microbiota and host immune system. We hypothesize that a low fiber diet is a critical, but understudied, factor in asthma health disparities. The overall goals of this proposal are to determine the effect of a gut microbiome modifier (fiber) on microbial composition and function in an underserved population. In addition, we will determine the effect of soluble fiber supplementation in reducing airway inflammation via the gut microbiome-airway axis. The hypothesis governing this proposal is that gut microbial metabolism of dietary fiber to SCFAs will reduce airway inflammation by altering the phenotype of T cells and eosinophils. We have assembled a strong team of clinicians and scientists, and we draw on our pilot study of fiber intervention in a pediatric asthma cohort to achieve 3 aims. First, we will build on the community partnerships through the PCH Mobile Asthma Clinic (Breathmobile) to assess baseline fiber consumption and gut microbiota across underserved communities in Maricopa County. Second, we will evaluate the effect of a soluble fiber supplement in a pediatric asthma cohort. Finally, we will evaluate the effect of microbial-derived SCFAs on key immune cell populations. Completion of these aims will provide evidence that can guide public health nutritional interventions in low SES populations to improve asthma outcomes and advance health equity.
项目概要 大约 7.7% 的美国人患有哮喘,且发病率自 20 世纪 80 年代以来一直在增加。在 亚利桑那州的哮喘患病率超过全国平均水平,大多数哮喘诊断是在该州进行的 凤凰城都会区。哮喘病的遗传危险因素已被确定。然而,稳定的 美国人口中哮喘患病率的增加表明,环境暴露或其他因素 饮食和肠道微生物群等肺外因素可能在哮喘发展中发挥关键作用。 低收入城市人群中哮喘患病率和发病率的健康差异凸显 更有可能存在营养健康差异的地区。例如,城市贫困人口的居住是 报告哮喘发作以及因哮喘相关就诊的可能性较高的个人风险因素 急诊科。少数民族儿童受到社会经济地位低下的影响尤为严重。一个 最近的研究表明,31.4% 的非西班牙裔黑人儿童和 25.2% 的西班牙裔儿童居住在 与 9.4% 的非西班牙裔白人儿童相比,该比例低于贫困线。经济困难 城市人口还面临着营养健康方面的差异,包括低纤维饮食,导致生活方式发生变化 肠道微生物组可能解释哮喘风险的差异。膳食纤维是复杂的碳水化合物, 抵抗小肠中宿主酶的代谢,并在结肠中被常驻微生物发酵。 可溶性纤维的肠道微生物发酵会产生代谢副产物,例如短纤维 链脂肪酸 (SCFA) 乙酸盐、丙酸盐和丁酸盐,它们是充当纽带的重要分子 微生物群和宿主免疫系统之间的关系。我们假设低纤维饮食至关重要,但是 哮喘健康差异的因素尚未得到充分研究。该提案的总体目标是确定效果 肠道微生物组修饰剂(纤维)对服务不足人群的微生物组成和功能的影响。在 此外,我们将通过以下方式确定补充可溶性纤维在减少气道炎症方面的效果: 肠道微生物组-气道轴。控制这一提议的假设是肠道微生物代谢饮食 将纤维转化为 SCFA 将通过改变 T 细胞和嗜酸性粒细胞的表型来减少气道炎症。我们有 我们组建了一支由临床医生和科学家组成的强大团队,我们利用纤维干预的试点研究 小儿哮喘队列旨在实现 3 个目标。首先,我们将通过 PCH 建立社区伙伴关系 移动哮喘诊所(Breathmobile)评估基线纤维消耗和肠道微生物群 马里科帕县服务不足的社区。其次,我们将评估可溶性纤维的效果 儿科哮喘队列中的补充剂。最后,我们将评估微生物衍生的 SCFA 对关键的影响 免疫细胞群。完成这些目标将为指导公共卫生提供证据 对低社会经济地位人群进行营养干预,以改善哮喘结果并促进健康公平。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Emily K Cope其他文献

Emily K Cope的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Emily K Cope', 18)}}的其他基金

Development of in vivo quantitative stable isotope probing to quantify microbiome dynamics in Alzheimers Disease
开发体内定量稳定同位素探测以量化阿尔茨海默病微生物组动态
  • 批准号:
    10473765
  • 财政年份:
    2021
  • 资助金额:
    $ 33.53万
  • 项目类别:
Development of in vivo quantitative stable isotope probing to quantify microbiome dynamics in Alzheimers Disease
开发体内定量稳定同位素探测以量化阿尔茨海默病微生物组动态
  • 批准号:
    10301904
  • 财政年份:
    2021
  • 资助金额:
    $ 33.53万
  • 项目类别:
Evaluation of Soluble Fiber as a Strategy to Decrease Asthma Morbidity in Underserved Populations
可溶性纤维作为降低服务不足人群哮喘发病率策略的评估
  • 批准号:
    10555413
  • 财政年份:
    2017
  • 资助金额:
    $ 33.53万
  • 项目类别:

相似国自然基金

微囊泡介导肺泡上皮祖细胞醋酸盐代谢重编程向AT2细胞分化促进ARDS炎症修复的作用机制
  • 批准号:
    82360020
  • 批准年份:
    2023
  • 资助金额:
    32 万元
  • 项目类别:
    地区科学基金项目
肝癌微环境富集醋酸盐增强内皮细胞乙酰化修饰并促进血管生成
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    52 万元
  • 项目类别:
    面上项目
络合萃取法提取生物油酚类化合物的效能及机理研究
  • 批准号:
    21206142
  • 批准年份:
    2012
  • 资助金额:
    25.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

ALDH2 inhibitors for the treatment of AUD
ALDH2抑制剂用于治疗AUD
  • 批准号:
    10664502
  • 财政年份:
    2023
  • 资助金额:
    $ 33.53万
  • 项目类别:
MECHANISMS OF VISCERAL PAIN DRIVEN BY SMALL INTESTINAL MICROBIOTA
小肠微生物驱动内脏疼痛的机制
  • 批准号:
    10836298
  • 财政年份:
    2023
  • 资助金额:
    $ 33.53万
  • 项目类别:
Development of pHLIP-phosphoantigen conjugates for lymphoma therapy
开发用于淋巴瘤治疗的 pHLIP-磷酸抗原缀合物
  • 批准号:
    10646988
  • 财政年份:
    2023
  • 资助金额:
    $ 33.53万
  • 项目类别:
Epigenetic and metabolic mechanisms of environmentally-induced transgenerational germline dysfunction
环境诱导的跨代种系功能障碍的表观遗传和代谢机制
  • 批准号:
    10606928
  • 财政年份:
    2023
  • 资助金额:
    $ 33.53万
  • 项目类别:
Polysaccharide putty formulations for tissue regeneration
用于组织再生的多糖腻子配方
  • 批准号:
    10627055
  • 财政年份:
    2023
  • 资助金额:
    $ 33.53万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了